Bausch Health Companies Inc. and Salix Pharmaceuticals have announced that they will be presenting the results of an analysis of Xifaxan (rifaximin) monotherapy at The American College of Gastroenterology 2024 Annual Scientific Meeting. The analysis evaluated the efficacy of Xifaxan monotherapy compared to lactulose monotherapy for reducing the risk of overt hepatic encephalopathy (OHE) recurrence and all-cause mortality.
During the ACG meeting, Salix will also present new data on the impact of Xifaxan use on rehospitalizations following discharge from an OHE hospitalization in both commercially insured and Medicare patient populations. Additionally, two posters will be presented at the meeting sharing findings for Plenvu (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride, and potassium chloride for oral solution) as a bowel preparation medication, including efficacy findings from colonoscopy patients with comorbid conditions or taking concomitant medications known to impact bowel prep quality.
“These presentations at ACG 2024 can provide healthcare professionals with confidence in the potential of Salix treatments to improve outcomes for their patients,” said Aimee Lenar, Executive Vice President, US Pharma at Bausch Health. “Bausch Health is committed to pursuing life-changing solutions and continues to invest in expanding the body of evidence for our medicines.”
The full list of Salix research and analyses to be presented at ACG 2024 includes:
XIFAXAN
– Rifaximin Monotherapy Is More Effective Than Lactulose Monotherapy for Reducing the Risk of OHE Recurrence and All-Cause Mortality: An Analysis of Two Randomized Trials
– Impact of Rifaximin Use on OHE Rehospitalizations Post Discharge from an OHE Hospitalization in Commercially and Medicare Insured Patients
PLENVU
– Efficacy and Safety of the 1 Liter NER1006 Bowel Preparation for Colonoscopy in Adults With Comorbid Conditions That May Impact Prep Quality
– One-Liter NER1006 Is Efficacious as a Bowel Preparation for Colonoscopy in Patients Taking Concomitant Medications Known to Impact Prep Quality
XIFAXAN is indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults. Important safety information includes contraindications in patients with hypersensitivity to rifaximin, risk of Clostridium difficile-associated diarrhea, increased systemic exposure in patients with severe hepatic impairment, and caution with concomitant use of P-glycoprotein (P-gp) and/or OATPs inhibitors.
PLENVU is a prescription medication used by adults to clean the colon before a colonoscopy. Important safety information includes precautions for patients with certain medical conditions, such as bowel obstruction or perforation, risks of dehydration and electrolyte imbalances, and potential side effects such as ulcers of the bowel or bowel problems.
Bausch Health Companies Inc. is a global diversified pharmaceutical company focused on delivering better healthcare outcomes. Their gastroenterology business, Salix Pharmaceuticals, is one of the largest specialty pharmaceutical businesses in the world, specializing in the treatment of gastrointestinal diseases. For more information about Salix and Bausch Health, visit their respective websites.
Investor and media contacts for Salix Pharmaceuticals are provided for further information on their presentations at ACG 2024. Visit the original press release on accesswire.com for more details.